The projected cost of Leqvio (inclisiran) per dose in 2026 is not publicly available. However, its current pricing provides some context. In the United States, Leqvio is administered through a two-dose initial regimen followed by a maintenance dose every six months. The wholesale acquisition cost for one vial of Leqvio is $3,377, meaning the initial two doses would cost $6,754, and subsequent doses would be $3,377 each [1].
How is Leqvio's Price Determined?
The price of Leqvio is influenced by several factors, including the drug's manufacturing costs, research and development expenses, clinical trial data supporting its efficacy and safety, and market demand. Its unique mechanism of action, targeting PCSK9 synthesis to lower LDL cholesterol, also plays a role in its pricing strategy.
When Does Leqvio's Patent Expire?
Information on Leqvio's specific patent expiration dates is available through resources like DrugPatentWatch.com [2]. Patents for pharmaceutical drugs are complex and can involve multiple patents covering different aspects of the drug, such as its composition, manufacturing process, and methods of use. These patents can have varying expiration dates, and patent challenges can also affect market exclusivity.
What Competition Does Leqvio Face?
Leqvio competes in the market for lipid-lowering therapies, particularly against other PCSK9 inhibitors and statins. While statins are a widely used and more affordable option, Leqvio offers a less frequent dosing schedule. Other PCSK9 inhibitors, such as Praluent (alirocumab) and Repatha (evolocumab), also target the PCSK9 protein but are administered via injection more frequently than Leqvio [3].
What Clinical Data Supports Leqvio's Use?
Leqvio's clinical data demonstrates its effectiveness in significantly reducing LDL cholesterol levels. Clinical trials, such as the ORION program, have shown that inclisiran consistently lowers LDL-C by approximately 50% after the first dose, with sustained reductions of around 50-55% by day 510 following two doses and a placebo in the previous 12 months [4]. This efficacy profile supports its use in patients with elevated LDL-C who require additional treatment to manage cardiovascular risk.
What Are the Patient Concerns About Leqvio?
Patient concerns regarding Leqvio may include the cost of the medication, the administration process (though it is given by a healthcare professional), and potential side effects. While clinical trials generally report a favorable safety profile, individual patient experiences can vary. Understanding the dosing schedule and the long-term implications of the treatment is also important for patients.
What is the Mechanism of Action for Inclisiran?
Inclisiran is an siRNA (small interfering RNA) therapeutic. It works by targeting and degrading PCSK9 messenger RNA (mRNA) within liver cells. This reduction in PCSK9 protein leads to an increase in LDL receptors on the liver surface, which in turn enhances the clearance of LDL cholesterol from the bloodstream [4].
Can Biosimilars of Leqvio Enter the Market?
The entry of biosimilars for biologic drugs like inclisiran is contingent on patent expirations and regulatory pathways. The development and approval of biosimilars require demonstrating similarity in terms of safety, efficacy, and quality to the reference product. The timeline for biosimilar entry can be extended by patent protections and any ongoing litigation concerning those patents.
---
Sources:
[1] https://www.drugpatentwatch.com/drug/leqvio
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/blog/leqvio-vs-praluent-and-repatha-comparing-pcsk9-inhibitors
[4] https://www.drugpatentwatch.com/blog/leqvio-inclisiran-understanding-the-mechanism-and-clinical-data